PPIDT00363
Drug Information
| Name | Bezlotoxumab |
|---|---|
| Sequence | EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB13140 |
| Type | biotech |
| Indication | Bezlotoxumab is indicated to reduce the recurrence of _Clostridioides difficile_ infection (CDI) in patients who are receiving antibacterial drug treatment for CDI and are at high risk for CDI recurrence.[L46976, L47191] In the US, the drug is approved for use in patients one year of age and older.[L46976] In Europe, it is approved in adults only.[L47191] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
25 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
25 mg/ml
|
| Injection, solution, concentrate | Intravenous; Parenteral |
25 MG/ML
|